|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated circulating osteoprotegerin (OPG) level is associated with an increased risk of hospitalization for ischemic stroke and coronary artery disease.
|
30658955 |
2019 |
|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher circulating OPN and OPG levels have been associated with the presence of insulin resistance, atherosclerosis and coronary heart disease.
|
30132286 |
2019 |
|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest another possible mechanism linking osteoprotegerin and osteopontin serum levels with CAD progression through arterial wall stiffening and inflammation.
|
31642412 |
2019 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct associations between plasma osteoprotegerin, homoarginine and asymmetric dimethylarginine in chronic kidney disease male patients with coronary artery disease.
|
31049693 |
2019 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
This narrative review analyzed information from >50 human studies, which strongly suggest that OPG, OPN, and alkaline phosphatase (ALP) serum concentrations are altered in patients with CAD.
|
30696256 |
2019 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion:</b> High OPG and high OPN levels, but not <i>OPG</i> rs2073618 CC genotype or <i>OPN</i> rs11730582 TT genotype, were strong predictors of mortality in both CAD and PAD patients.
|
31157557 |
2019 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic significance of arterial stiffness and osteoprotegerin in patients with stable coronary artery disease.
|
29330911 |
2018 |
|
TNFRSF11B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of osteoprotegerin, a secreted tumor necrosis factor-related molecule, might be associated with adverse outcomes in patients with coronary artery disease.
|
29330256 |
2018 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease).
|
28837646 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The number of diseased vessels (a marker of the severity of coronary atherosclerosis) and the Gensini score (a marker of the extent of coronary atherosclerosis), as well as the OPG and TRACP-5b levels were measured in CAD patients.
|
28428481 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL) are regulators of bone remodeling, but are also considered to play important roles in coronary artery disease (CAD).
|
28567553 |
2017 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore this possibility, we determined the mRNA expression by qPCR of a pro-calcifying gene (osteopontin (OPN)), and two anti-calcifying genes (osteoprotegerin (OPG) and osteonectin (ON)), in biopsies of EAT obtained from 15 patients with coronary artery disease (CAD) determined by angiography, and 15 patients with diagnostic of aortic valve stenosis but without CAD as control group.
|
28821297 |
2017 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the frequency of OPG gene polymorphisms in patients with CAD and to analyse the relationship between the severity of CAD and BMD.
|
21678294 |
2011 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since elevated plasma levels of osteoprotegerin (OPG) represent a risk factor for death and heart failure in patients affected by diabetes mellitus and coronary artery disease, this study aimed to elucidate potential roles of OPG in the pathogenesis of atherosclerosis.
|
19907187 |
2010 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on its role in inflammation and matrix degradation, we hypothesized a role for osteoprotegerin (OPG), RANK, and RANK ligand (RANKL) in coronary artery disease.
|
16424351 |
2006 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, the aim of this study was to investigate the relationship between OPG gene polymorphisms and aortic calcification or coronary artery disease in Koreans.
|
16712673 |
2006 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men.
|
16678184 |
2006 |
|
TNFRSF11B
|
0.100 |
Biomarker
|
disease |
LHGDN |
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.
|
16123486 |
2005 |
|
TNFRSF11B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, linkage of genetic variations of the OPG gene at positions 950 and 1181 may confer an increased risk of CAD in Caucasian men.
|
15292302 |
2004 |